Novo hemophila drug approved

Share this article:

The FDA approved Novo Nordisk's Hemophilia A drug Novoeight. The Danish drug maker said in a statement Wednesday that it expects to have the drug on the US market during 2015's second quarter.

The treatment is for a type of hemophilia that typically affects men, and is the result of a missing or malfunctioning factor VIII protein.

The drug was among an elite list of medications approved during the government's 16-day shutdown.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.